# B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B

> **NCT04193189** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 638 (actual)

## Conditions studied

- HIV Infection
- Hepatitis B

## Interventions

- **BIOLOGICAL:** HEPLISAV-B
- **BIOLOGICAL:** ENGERIX-B

## Key facts

- **NCT ID:** NCT04193189
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-14
- **Primary completion:** 2024-08-13
- **Final completion:** 2024-08-13
- **Target enrollment:** 638 (ACTUAL)
- **Last updated:** 2025-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04193189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04193189, "B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT04193189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*